The UK and US have agreed to a important commercial pact that will keep no import taxes on UK pharmaceutical exports being sold in the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to boost spending on medicines through the National Health Service (NHS). This move ensures that import taxes on these vital products will be held at zero for a period of three years.
This development comes after recent threats to dramatically increase duties on patented drug imports, with increases floated as high as one hundred percent.
"This deal between the United Kingdom reinforces the global environment for new treatments and brings much-needed fairness to U.S.–U.K. drug exports," a statement noted.
Economic Significance
Pharmaceuticals constitute one of the Britain's most significant export categories to the America, which is easily the biggest buyer for large UK drugmakers.
Trade data reveal that in the 12 months prior to the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This value accounted for 17.4% of British export trade in that period.
"This deal safeguards work, increases funding and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary stated.
Specific British Pledges
The deal includes several key pledges from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total public funding on medicines from 0.3% of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. Previously, refunds were more than twenty percent.
Industry Background
The pact comes amid a long-running row between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
This friction were exacerbated by arguments that American consumers were paying several times more for the same drugs than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or abandoned, while substantial funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
